In the autologous setting, high-dose therapy is at present supported by blood stem cells in about 99% of patients. Blood stem cells are collected after mobilization with G-CSF alone or combined with chemotherapy. A significant proportion of patients, however, are difficult to mobilize or fail to mobilize enough stem cells to start apheresis. According to a recent large single-center series, the failure rates (o2 Â 10 6 /kg CD34 þ cells collected with maximum of five aphereses after a single mobilization attempt) were about 26% for patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) and about 6% in patients with multiple myeloma (MM); more than 90% of the patients were mobilized with G-CSF alone. 1 In our own experience using chemotherapy combined with G-CSF (CT þ G-CSF) mobilization, the failure rates were 16% in patients with NHL (41 of 258), 13% in patients with HL (5 of 40) and 3% (6 of 178) in patients with MM.
Selection of mobilization regimen used in patients with lymphoproliferative diseases depends on many issues.
2,3
Several patient and disease-related characteristics influence the decision as well as institutional experience and practices. In many lymphoma patients there may be a clinical need to use chemotherapy for the treatment of malignancy and hence the use of chemotherapy regimen followed by G-CSF for stem cell mobilization is straightforward. However, in myeloma patients after effective induction therapy, the use of CY for stem cell mobilization alone has little effect in terms of treatment response. 4 Mobilization regimen consisting of CT þ G-CSF resulted in higher numbers of stem cells being collected.
1-3 However, chemotherapy-based mobilization is more toxic and needs more supportive care as well other resources.
Plerixafor is a selective and reversible antagonist of CXCR4 and interrupts its interaction with SDF-1 causing a rapid release of stem cells from marrow to circulation. When compared with G-CSF alone, the combination of plerixafor with G-CSF was found to be more efficient in terms of stem cell mobilization capacity. 5, 6 Combination of plerixafor with G-CSF mobilization has proved successful in about 70% of patients with NHL, HL or MM who had failed a previous mobilization attempt with G-CSF alone or in combination with chemotherapy. 7 In two phase III placebo-controlled randomized trials a combination of plerixafor with G-CSF resulted in superior stem cell mobilization when compared to G-CSF alone both in patients with MM 8 and in patients with NHL. 9 Plerixafor was approved by European Medicines Agency (EMEA) in 2009 for clinical use in combination with G-CSF in patients with lymphoma or MM whose cells mobilize poorly. Not only in lymphoma patients but also in some myeloma patients clinicians may prefer the use of chemotherapy combined with G-CSF for stem cell mobilization to improve the control of underlying malignancy. Unfortunately, there is limited information on the use of plerixafor after CT þ G-CSF mobilization in patients with lymphoproliferative diseases. Especially this deals with optimal dosing and timing of plerixafor. A notable exception is a recent open-label multicenter study from the United States including 14 NHL and 26 MM patients. 10 Although of importance to delineate safety and preliminary efficacy of plerixafor in this context, most of the patients included in that study cannot be considered as poor mobilizers because almost all had sufficient stem cell collections already before plerixafor injection(s). We describe here our experiences in using add-on plerixafor in patients who had previously failed a CT þ G-CSF mobilization or who mobilized poorly after the first mobilization attempt with a CT þ G-CSF regimen.
There were four men and three women with a median age of 61 years (55-68 years) ( Table 1) . Six patients had NHL (four with diffuse large B-cell lymphoma, one with mantle cell lymphoma and one with follicular lymphoma). One patient had MM with severe renal failure (dialysis dependent for almost a year). Two patients had failed an earlier mobilization with CT þ G-CSF (no collections due to low B-CD34 þ counts). Five patients were mobilized with high-dose cytarabine-based regimen and two with CY followed by G-CSF. In six patients B-CD34 þ counts remained low (o1-7 Â 10 6 /L) despite rising leukocyte counts (2.1 to 34.6 Â 10 9 /L) or decreased after a low peak (10 Â 10 6 /L; n ¼ 1) just before plerixafor injection. The patients received 1-3 injections (median 1) of plerixafor. Blood CD34 þ counts rose to 9, 30, 39, 39, 40 and 86 Â 10 6 /L in six patients, whereas no response was observed in one patient (maximum 1 Â 10 6 /L). In six out of seven patients the collections were successful after the addition of plerixafor with a median of one apheresis (Table 1) . Five patients subsequently received BEAM chemotherapy supported by peripheral blood grafts mobilized with CT þ G-CSF with add-on plerixafor with successful engraftment in all patients (but delayed platelet engraftment in one patient).
Although mobilization with G-CSF alone will give satisfactory collections in the majority of patients with MM, the situation is different in most lymphoma patients considered for auto-SCT. In these circumstances, mobilization with CT þ G-CSF might be preferred. If a patient mobilizes poorly (CD34 þ cell count o5-10 at the time of leukocyte recovery) or 1-2 collections yield poor CD34 þ numbers, add-on plerixafor might be an efficient and costeffective approach to facilitate successful collection to proceed to high-dose therapy. This may be a more cost-effective approach than a remobilization attempt or BM harvest. There seems to be need for studies evaluating how to combine plerixafor to CT þ G-CSF mobilization in terms of optimal timing and dosing. Based on this preliminary experience in a small group of patients, the optimal timing might be when the leukocyte count has recovered after the nadir but there is scanty amount of CD34 þ cells in the blood. Although further studies are clearly needed, plerixafor seems to be a useful addition to our armamentarium for hard-to-mobilize patients. It may also prove to be costeffective in some patients with only moderate stem cell mobilization capacity with standard regimens to decrease the amount of collections and all associated logistics.
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